Results 201 to 210 of about 22,288 (223)

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2020
Pravin U Dugel, Adrian Koh, Yuichiro Ogura   +2 more
exaly  

One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry

Ophthalmology, 2023
Charles C Wykoff, Hélène Karcher, Eser Adiguzel   +2 more
exaly  

Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration

Ophthalmology, 2020
Panos G Christakis, Elvira Agron, Traci E Clemons   +2 more
exaly  

Neovascular age-related macular degeneration

2010
David E Lederer, Scott W Cousins, Karl G Csaky   +2 more
openaire   +2 more sources

<p>Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration</p>

Clinical Ophthalmology, 2019
K Bailey Freund
exaly  

Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2018
Srinivas R Sadda, Beiying Ding, Anne E Fung   +2 more
exaly  

Neovascular Age-Related Macular Degeneration

2006
ADAM H. ROGERS, ANDRE WITKIN
openaire   +1 more source

Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration

Ophthalmology, 2016
Maureen G Maguire, Daniel F Martin, Gui-Shuang Ying   +2 more
exaly  

Two-Year Outcomes of “Treat and Extend” Intravitreal Therapy for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2015
Jennifer J Arnold, Anna Campain, Daniel Barthelmes   +2 more
exaly  

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen

Ophthalmology, 2019
Mark C Gillies, Alex P Hunyor, Andrew Chang   +2 more
exaly